Advanced search
Publication Cover
Therapeutic Delivery Volume 3, 2012 - Issue 8
Submit an article Journal homepage
192
Views
0
CrossRef citations to date
0
Altmetric
Review

Targeting Malignant Mitochondria With Therapeutic Peptides

Jonathan E Constance1 Department of Pharmacology & Toxicology College of Pharmacy University of UtahSalt Lake CityUT84108USA
&
Carol S Lim2 Department of Pharmaceutics & Pharmaceutical Chemistry College of Pharmacy University of Utah421 Wakara WayRoom 318Salt Lake [email protected]
Pages 961-979 | Published online: 23 Aug 2012

References

  • Ralph SJ , Rodriguez-EnriquezS, NeuzilJ, SaavedraE, Moreno-SanchezR. The causes of cancer revisited: “mitochondrial malignancy” and ROS-induced oncogenic transformation – why mitochondria are targets for cancer therapy. Mol. Aspects Med.31(2), 145–170 (2010).
  • McCarty MF . Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr. Cancer Ther.3(4), 349–380 (2004).
  • Mahato RI , NarangAS, ThomaL, MillerDD. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst.20(2–3), 153–214 (2003).
  • Tan ML , ChoongPF, DassCR. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides31(1), 184–193 (2010).
  • Green DR , FergusonT, ZitvogelL, KroemerG. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol.9(5), 353–363 (2009).
  • Ieva E , TrapaniA, CioffiN, DitarantoN, MonopoliA, SabbatiniL. Analytical characterization of chitosan nanoparticles for peptide drug delivery applications. Anal. Bioanal. Chem.393(1), 207–215 (2009).
  • Torchilin VP . Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev.60(4–5), 548–558 (2008).
  • Martins I , MichaudM, SukkurwalaAQet al. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 8(3) (2012) (Epub ahead of print).
  • Gogvadze V , ZhivotovskyB, OrreniusS. The warburg effect and mitochondrial stability in cancer cells. Mol. Aspects Med.31(1), 60–74 (2010).
  • Wemeau M , KeppO, TesniereAet al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 1, e104 (2010).
  • Bitler BG , SchroederJA. Anti-cancer therapies that utilize cell penetrating peptides. Recent Pat. Anticancer Drug Discov.5(2), 99–108 (2010).
  • Fulda S , GalluzziL, KroemerG. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov.9(6), 447–464 (2010).
  • Hortobagyi GN . Trastuzumab in the treatment of breast cancer. N. Engl. J. Med.353(16), 1734–1736 (2005).
  • Nakase I , KonishiY, UedaM, SajiH, FutakiS. Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo. J. Control. Release159(2), 181–188 (2012).
  • Christofk HR , Vander Heiden MG, Harris MH et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature452(7184), 230–233 (2008).
  • Mossalam M , DixonAS, LimCS. Controlling subcellular delivery to optimize therapeutic effect. Therapeutic Delivery1(1), 169–193 (2010).
  • Seyfried TN , SheltonLM. Cancer as a metabolic disease. Nutr. Metab. (Lond.).27(7), 7 (2010).
  • Chonghaile TN , SarosiekKA, VoTTet al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334(6059), 1129–1133 (2011).
  • Galluzzi L , KroemerG. Necroptosis: a specialized pathway of programmed necrosis. Cell135(7), 1161–1163 (2008).
  • Atay C , UgurluS, OzorenN. Shock the heat shock network. J. Clin. Invest.119(3), 445–448 (2009).
  • Martinou JC , YouleRJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev. Cell21(1), 92–101 (2011).
  • Chipuk JE , KuwanaT, Bouchier-HayesLet al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303(5660), 1010–1014 (2004).
  • Kutuk O , LetaiA. Regulation of Bcl-2 family proteins by posttranslational modifications. Curr. Mol. Med.8(2), 102–118 (2008).
  • Szabo I , SoddemannM, LeanzaL, ZorattiM, GulbinsE. Single-point mutations of a lysine residue change function of Bax and Bcl-xL expressed in Bax- and Bak-less mouse embryonic fibroblasts: novel insights into the molecular mechanisms of Bax-induced apoptosis. Cell Death Differ.18(3), 427–438 (2011).
  • Szabo I , BockJ, GrassmeHet al. Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes. Proc. Natl Acad. Sci. USA 105(39), 14861–14866 (2008).
  • Cipolat S , RudkaT, HartmannDet al. Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling. Cell 126(1), 163–175 (2006).
  • Liu T , HannafonB, GillL, KellyW, BenbrookD. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol. Cancer Ther.6(6), 1814–1822 (2007).
  • Griffin C , KarnikA, McNultyJ, PandeyS. Pancratistatin selectively targets cancer cell mitochondria and reduces growth of human colon tumor xenografts. Mol. Cancer Ther.10(1), 57–68 (2011).
  • Vella S , ContiM, TassoR, CanceddaR, PaganoA. Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells. Int. J. Cancer130(7), 1484–1493 (2012).
  • Bellance N , LestienneP, RossignolR. Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front. Biosci.14, 4015–4034 (2009).
  • Gupta SC , HeviaD, PatchvaS, ParkB, KohW, AggarwalBB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid. Redox Signal.16(11), 1295–1322 (2012).
  • Diehn M , ChoRW, LoboNAet al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239), 780–783 (2009).
  • Ishikawa K , TakenagaK, AkimotoMet al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320(5876), 661–664 (2008).
  • Bair JS , PalchaudhuriR, HergenrotherPJ. Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death. J. Am. Chem. Soc.132(15), 5469–5478 (2010).
  • Atlante A , CalissanoP, BobbaA, AzzaritiA, MarraE, PassarellaS. Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death. J. Biol. Chem.275(47), 37159–37166 (2000).
  • Song IS , KimHK, JeongSHet al. Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int. J. Mol. Sci. 12(10), 7163–7185 (2011).
  • Yu GR , QinWW, LiJPet al. HIV-TAT-fused FHIT protein functions as a potential pro-apoptotic molecule in hepatocellular carcinoma cells. Biosci. Rep. 32(3), 271–279 (2012).
  • Martin J , St-PierreMV, DufourJF. Hit proteins, mitochondria and cancer. Biochim. Biophys. Acta1807(6), 626–632 (2011).
  • Svilar D , GoellnerEM, AlmeidaKH, SobolRW. Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. Antioxid. Redox Signal.14(12), 2491–2507 (2011).
  • Houston MA , AugenlichtLH, HeerdtBG. Stable differences in intrinsic mitochondrial membrane potential of tumor cell subpopulations reflect phenotypic heterogeneity. Int. J. Cell Biol.6(9), e25207 (2011).
  • Xue X , YouS, ZhangQet al. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction. Mol. Pharm. 9(3), 634–644 (2012).
  • Fukuda R , ZhangH, KimJW, ShimodaL, DangCV, SemenzaGL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell129(1), 111–122 (2007).
  • Lecoeur H , Borgne-SanchezA, ChaloinOet al. HIV-1 Tat protein directly induces mitochondrial membrane permeabilization and inactivates cytochrome c oxidase. Cell Death Dis. 3, E282 (2012).
  • Nonaka M , HashimotoY, TakeshimaSN, AidaY. The human immunodeficiency virus type 1 Vpr protein and its carboxy-terminally truncated form induce apoptosis in tumor cells. Cancer Cell Int.12(9), 20 (2009).
  • Arcangeli A , CrocianiO, LastraioliE, MasiA, PillozziS, BecchettiA. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr. Med. Chem.16(1), 66–93 (2009).
  • Szabo I , LeanzaL, GulbinsE, ZorattiM. Physiology of potassium channels in the inner membrane of mitochondria. Pflugers Arch.463(2), 231–246 (2012).
  • Cardoso AR , QueliconiBB, KowaltowskiAJ. Mitochondrial ion transport pathways: role in metabolic diseases. Biochim. Biophys. Acta1797(6–7), 832–838 (2010).
  • Felipe A , BielanskaJ, ComesNet al. Targeting the voltage-dependent k(+) channels kv1.3 and kv1.5 as tumor biomarkers for cancer detection and prevention. Curr. Med. Chem. 19(5), 661–674 (2012).
  • Kosztka L , RusznakZ, NagyDet al. Inhibition of TASK-3 (KCNK9) channel biosynthesis changes cell morphology and decreases both DNA content and mitochondrial function of melanoma cells maintained in cell culture. Melanoma Res. 21(4), 308–322 (2011).
  • De Stefani D , RaffaelloA, TeardoE, SzaboI, RizzutoR. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature476(7360), 336–340 (2011).
  • Wong R , SteenbergenC, MurphyE. Mitochondrial permeability transition pore and calcium handling. Methods Mol. Biol.810, 235–242 (2012).
  • Cao X , ZhuH, Ali-OsmanF, LoHW. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis. Mol. Cancer10, 26 (2011).
  • Ren J , BhartiA, RainaD, ChenW, AhmadR, KufeD. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene25(1), 20–31 (2006).
  • Sharma SV , BellDW, SettlemanJ, HaberDA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer7(3), 169–181 (2007).
  • Zhu H , CaoX, Ali-OsmanF, KeirS, LoHW. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer Lett.294(1), 101–110 (2010).
  • Cruickshanks N , HamedH, BarefordMDet al. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Mol. Pharmacol. 81(5), 748–758 (2012).
  • Yin L , KufeD. MUC1-C oncoprotein blocks terminal differentiation of chronic myelogenous leukemia cells by a ROS-mediated mechanism. Genes Cancer2(1), 56–64 (2011).
  • Yin L , KosugiM, KufeD. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood119(3), 810–816 (2012).
  • Kim TH , ZhaoY, DingWXet al. Bid-cardiolipin interaction at mitochondrial contact site contributes to mitochondrial cristae reorganization and cytochrome C release. Mol. Biol. Cell 15(7), 3061–3072 (2004).
  • Huang CY , ChiangSF, LinTY, ChiouSH, ChowKC. HIV-1 Vpr triggers mitochondrial destruction by impairing Mfn2-mediated ER-mitochondria interaction. PLoS One7(3), E33657 (2012).
  • Sabbah EN , DruillennecS, MorelletN, BouazizS, KroemerG, RoquesBP. Interaction between the HIV-1 protein Vpr and the adenine nucleotide translocator. Chem. Biol. Drug Des.67(2), 145–154 (2006).
  • Boya P , PauleauAL, PoncetD, Gonzalez-PoloRA, ZamzamiN, KroemerG. Viral proteins targeting mitochondria: controlling cell death. Biochim. Biophys. Acta1659(2–3), 178–189 (2004).
  • Ko JK , ChoiKH, PengJet al. Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 (BH3) peptides from Bcl-2 family proteins induce apoptosis through different mechanisms. J. Biol. Chem. 286(11), 9038–9048 (2011).
  • Papo N , ShaiY. New lytic peptides based on the d.l-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry42(31), 9346–9354 (2003).
  • Madan V , Sanchez-MartinezS, CarrascoL, NievaJL. A peptide based on the pore-forming domain of pro-apoptotic poliovirus 2B viroporin targets mitochondria. Biochim. Biophys. Acta1798(1), 52–58 (2010).
  • Szewczyk A , WojtczakL. Mitochondria as a pharmacological target. Pharmacol. Rev.54(1), 101–127 (2002).
  • Ellerby HM , ArapW, EllerbyLMet al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5(9), 1032–1038 (1999).
  • Fantin VR , BerardiMJ, BabbeH, MichelmanMV, ManningCM, LederP. A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. Cancer Res.65(15), 6891–6900 (2005).
  • Smolarczyk R , CichonT, GrajaK, HuczJ, SochanikA, SzalaS. Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model. Acta Biochim. Pol.53(4), 801–805 (2006).
  • Galluzzi L , KeppO, Trojel-HansenC, KroemerG. Non-apoptotic functions of apoptosis-regulatory proteins. EMBO Rep.13(4), 322–330 (2012).
  • Rudner J , ElsaesserSJ, MullerAC, BelkaC, JendrossekV. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Biochem. Pharmacol.79(1), 10–20 (2010).
  • Schoenwaelder SM , JacksonSP. Bcl-xL-inhibitory BH3 mimetics (ABT-737 or ABT-263) and the modulation of cytosolic calcium flux and platelet function. Blood119(5), 1320–1321; author reply 1321–1322 (2012).
  • Holinger EP , ChittendenT, LutzRJ. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem.274(19), 13298–13304 (1999).
  • Dharap SS , MinkoT. Targeted proapoptotic LHRH-BH3 peptide. Pharm. Res.20(6), 889–896 (2003).
  • Pitter K , BernalF, LabelleJ, WalenskyLD. Dissection of the BCL-2 family signaling network with stabilized α-helices of BCL-2 domains. Methods Enzymol.446, 387–408 (2008).
  • Katz SG , LabelleJL, GodesM, FisherJ, BirdGH, WalenskyLD. A stapled BIM BH3 helix restores apoptosis in bim-null mantle cell lymphoma. Presented at: American Society of Hematology Annual Meeting. Atlanta, GA, USA, 4–7 December 2010.
  • Ponassi R , BiasottiB, TomatiVet al. A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex vivo anti-leukemic activity. Cell Cycle 7(20), 3211–3224 (2008).
  • Gangoda L , MoujalledD, LeeY, RahimiA, PuthalakathH. Analysis of the role of Bim as a tumor suppressor in Carney complex syndrome. In: Cell Death in Cancer. De Rode Hoed, Amsterdam, The Netherlands (2012).
  • Rong YP , BultynckG, AromolaranASet al. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc. Natl Acad. Sci. USA 106(34), 14397–14402 (2009).
  • Iqbal S , ZhangS, DrissAet al. PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells. PLoS One 7(1), E30764 (2012).
  • Zhong F , HarrMW, BultynckGet al. Induction of Ca(2)+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction. Blood 117(10), 2924–2934 (2011).
  • Elgendy M , SheridanC, BrumattiG, MartinSJ. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol. Cell42(1), 23–35 (2011).
  • Garg AD , KryskoDV, VerfaillieTet al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 31(5), 1062–1079 (2012).
  • Cristofanon S , FuldaS. ABT-737 promotes tBid mitochondrial insertion to enhance TRAIL-induced apoptosis in glioblastoma cells. In: Cell Death in Cancer. De Rode Hoed, Amsterdam, The Netherlands (2012).
  • Glaser SP , LeeEF, TrounsonEet al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26(2), 120–125 (2012).
  • Stewart ML , FireE, KeatingAE, WalenskyLD. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat. Chem. Biol.6(8), 595–601 (2010).
  • Galluzzi L , KeppO, TajeddineN, KroemerG. Disruption of the hexokinase-VDAC complex for tumor therapy. Oncogene27(34), 4633–4635 (2008).
  • Brenner C , GrimmS. The permeability transition pore complex in cancer cell death. Oncogene25(34), 4744–4756 (2006).
  • Shoshan-Barmatz V , De Pinto V, Zweckstetter M, Raviv Z, Keinan N, Arbel N. VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol. Aspects Med.31(3), 227–285 (2010).
  • Rupprecht R , PapadopoulosV, RammesGet al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat. Rev. Drug Discov. 9(12), 971–988 (2010).
  • Taliani S , PugliesiI, Da Settimo F. Structural requirements to obtain highly potent and selective 18 kDa translocator protein (TSPO) Ligands. Curr. Top Med. Chem.11(7), 860–886 (2011).
  • Chiara F , CastellaroD, MarinOet al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS One 3(3), E1852 (2008).
  • Masgras I , RasolaA, BernardiP. Induction of the permeability transition pore in cells depleted of mitochondrial DNA. Biochim. Biophys. Acta (2012) (Epub ahead of print).
  • Borgne-Sanchez A , DupontS, LangonneAet al. Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of αVβ3-expressing endothelial cells. Cell Death Differ. 14(3), 422–435 (2007).
  • Park D , ChiuJ, PerroneGG, DildaPJ, HoggPJ. The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase. Cancer Cell Int.12(1), 11 (2012).
  • Dilda PJ , DecollogneS, WeerakoonLet al. Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol. J. Med. Chem. 52(20), 6209–6216 (2009).
  • Banerjee J , GhoshS. Bax increases the pore size of rat brain mitochondrial voltage-dependent anion channel in the presence of tBid. Biochem. Biophys. Res. Commun.323(1), 310–314 (2004).
  • Shoshan-Barmatz V , Ben-HailD. VDAC, a multi-functional mitochondrial protein as a pharmacological target. Mitochondrion12(1), 24–34 (2012).
  • Gergalova G , LykhmusO, KalashnykOet al. Mitochondria express α7 nicotinic acetylcholine receptors to regulate Ca accumulation and cytochrome c release: study on isolated mitochondria. PLoS One 7(2), E31361 (2012).
  • Karbowski M , NorrisKL, ClelandMM, JeongSY, YouleRJ. Role of Bax and Bak in mitochondrial morphogenesis. Nature443(7112), 658–662 (2006).
  • Rosenfeldt MT , RyanKM. The multiple roles of autophagy in cancer. Carcinogenesis32(7), 955–963 (2011).
  • White EJ , MartinV, LiuJLet al. Autophagy regulation in cancer development and therapy. Am. J. Cancer Res. 1(3), 362–372 (2011).
  • Hoyer-Hansen M , JaattelaM. Autophagy: an emerging target for cancer therapy. Autophagy4(5), 574–580 (2008).
  • Gomes LC , Di Benedetto G, Scorrano L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat. Cell. Biol.13(5), 589–598 (2011).
  • Blackstone C , ChangCR. Mitochondria unite to survive. Nat. Cell Biol.13(5), 521–522 (2011).
  • Zorzano A , SebastianD, SegalesJ, PalacinM. The molecular machinery of mitochondrial fusion and fission: an opportunity for drug discovery? Curr. Opin. Drug Discov. Devel.12(5), 597–606 (2009).
  • Mossalam M , MatissekKJ, OkalA, ConstanceJE, LimCS. Direct induction of apoptosis using an optimal mitochondrially targeted p53. Mol. Pharm.9(5), 1449–1458 (2012).
  • Ferecatu I , BergeaudM, Rodriguez-EnfedaqueAet al. Mitochondrial localization of the low level p53 protein in proliferative cells. Biochem. Biophys. Res. Commun. 387(4), 772–777 (2009).
  • Bergeaud M , MathieuL, Le Floch N, Mignotte B, Rincheval V, Vayssiere JL. Localization and function of p53 protein at mitochondria in proliferative cells. In: Cell Death in Cancer. De Rode Hoed, Amsterdam, The Netherlands (2012).
  • Von Der Malsburg K , MullerJM, BohnertMet al. Dual role of mitofilin in mitochondrial membrane organization and protein biogenesis. Dev. Cell 21(4), 694–707 (2011).
  • Alirol E , MartinouJC. Mitochondria and cancer: is there a morphological connection? Oncogene25(34), 4706–4716 (2006).
  • Bouleau S , Parvu-FerecatuI, Rodriguez-EnfedaqueAet al. Fibroblast growth factor 1 inhibits p53-dependent apoptosis in PC12 cells. Apoptosis 12(8), 1377–1387 (2007).
  • Mossalam M , MatissekKJ, OkalA, ConstanceJE, LimCS. Direct induction of apoptosis using an optimal mitochondrially targeted p53. Mol. Pharm.9(5), 1449–1458 (2012).
  • Barnes DJ , PalaiologouD, PanousopoulouEet al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 65(19), 8912–8919 (2005).
  • Wang JY . Nucleo-cytoplasmic communication in apoptotic response to genotoxic and inflammatory stress. Cell Res.15(1), 43–48 (2005).
  • Ito Y , PandeyP, MishraNet al. Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis. Mol. Cell. Biol. 21(18), 6233–6242 (2001).
  • Lasfer M , DavenneL, VadrotNet al. Protein kinase PKCδ and c-Abl are required for mitochondrial apoptosis induction by genotoxic stress in the absence of p53, p73 and Fas receptor. FEBS Lett. 580(11), 2547–2552 (2006).
  • Constance JE , DespresSD, NishidaA, LimCS. Selective targeting of c-Abl via a cryptic mitochondrial targeting signal activated by cellular redox status in leukemic and breast cancer cells. Pharm. Res.29(8), 2317–2328 (2012).
  • Katz C , Zaltsman-AmirY, MostizkyY, KolletN, GrossA, FriedlerA. Molecular basis of the interaction between the pro apoptotic tBID protein and mitochondrial carrier homologue 2 (MTCH2): key players in the mitochondrial death pathway. J. Biol. Chem.287(18), 15016–15023 (2012).
  • Zaltsman Y , ShachnaiL, Yivgi-OhanaNet al. MTCH2/MIMP is a major facilitator of tBID recruitment to mitochondria. Nat. Cell. Biol. 12(6), 553–562 (2010).
  • Holley AK , DharSK, XuY, St Clair DK. Manganese superoxide dismutase: beyond life and death. Amino Acids42(1), 139–158 (2012).
  • Pedram A , RazandiM, WallaceDC, LevinER. Functional estrogen receptors in the mitochondria of breast cancer cells. Mol. Biol. Cell17(5), 2125–2137 (2006).
  • Ennen M , MinigV, GrandemangeSet al. Regulation of the high basal expression of the manganese superoxide dismutase gene in aggressive breast cancer cells. Free Radic. Biol. Med. 50(12), 1771–1779 (2011).
  • Zhao Y , ChaiswingL, VelezJMet al. p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. Cancer Res. 65(9), 3745–3750 (2005).
  • Altieri DC , SteinGS, LianJB, LanguinoLR. TRAP-1, the mitochondrial Hsp90. Biochim. Biophys. Acta1823(3), 767–773 (2012).
  • Dai C , WhitesellL. HSP90: a rising star on the horizon of anticancer targets. Future Oncol.1(4), 529–540 (2005).
  • Kamal A , ThaoL, SensintaffarJet al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425(6956), 407–410 (2003).
  • Xu H , ShiY, WangJet al. A heat shock protein 90 binding domain in endothelial nitric-oxide synthase influences enzyme function. J. Biol. Chem. 282(52), 37567–37574 (2007).
  • Siegelin MD , DohiT, RaskettCMet al. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J. Clin. Invest. 121(4), 1349–1360 (2011).
  • Kang BH , TavecchioM, GoelHLet al. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. Br. J. Cancer 104(4), 629–634 (2011).
  • Plescia J , SalzW, XiaFet al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7(5), 457–468 (2005).
  • Horibe T , KawamotoM, KohnoM, KawakamiK. Cytotoxic activity to acute myeloid leukemia cells by Antp-TPR hybrid peptide targeting Hsp90. J. Biosci. Bioeng. (2012).
  • Seigneuric R , GobboJ, ColasP, GarridoC. Targeting cancer with peptide aptamers. Oncotarget2(7), 557–561 (2011).
  • Szeto HH , SchillerPW. Novel therapies targeting inner mitochondrial membrane – from discovery to clinical development. Pharm. Res.28(11), 2669–2679 (2011).
  • Weiss A , BrillB, BorghoutsC, DelisN, MackL, GronerB. Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth. J. Cancer Res. Clin. Oncol.138(7), 1205–1220 (2012).
  • Shirakata T , OkaY, NishidaSet al. WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer. Anticancer Res. 32(3), 1081–1085 (2012).
  • Sinthuvanich C , VeigaAS, GuptaK, GasparD, BlumenthalR, SchneiderJP. Anticancer ss-hairpin peptides: membrane-induced folding triggers activity. J. Am. Chem. Soc.134(14), 6210– 6217 (2012).
  • Verdine GL . Drugging the ‘undruggable‘. Harvey Lect.102, 1–15 (2006).
  • Borghouts C , KunzC, GronerB. Current strategies for the development of peptide-based anti-cancer therapeutics. J. Pept. Sci.11(11), 713–726 (2005).
  • Zhai D , GodoiP, SergienkoEet al. High-throughput fluorescence polarization assay for chemical library screening against anti-apoptotic Bcl-2 family member Bfl-1. J. Biomol. Screen 17(3), 350–360 (2012).
  • Verdine GL , WalenskyLD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res.13(24), 7264–7270 (2007).
  • Bolhassani A . Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim. Biophys. Acta1816(2), 232–246 (2011).
  • Kelley SO , StewartKM, MourtadaR. Development of novel peptides for mitochondrial drug delivery: amino acids featuring delocalized lipophilic cations. Pharm. Res.28(11), 2808–2819 (2011).
  • Moreau V , FleuryC, PiquerDet al. PEPOP: computational design of immunogenic peptides. BMC Bioinformatics 9, 71 (2008).
  • Van Walle I , GansemansY, ParrenPW, StasP, LastersI. Immunogenicity screening in protein drug development. Expert Opin. Biol. Ther.7(3), 405–418 (2007).
  • Chirino AJ , AryML, MarshallSA. Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today9(2), 82–90 (2004).
  • Watt PM . Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat. Biotechnol.24(2), 177–183 (2006).
  • Braun CR , MintserisJ, GavathiotisE, BirdGH, GygiSP, WalenskyLD. Photoreactive stapled BH3 peptides to dissect the BCL-2 family interactome. Chem. Biol.17(12), 1325–1333 (2010).
  • Valero JG , SanceyL, KucharczakJet al. Bax-derived membrane-active peptides act as potent and direct inducers of apoptosis in cancer cells. J. Cell. Sci. 124(Pt 4), 556–564 (2011).
  • Trusheim M , AitkenMC, BerndtER. Characterizing markets for biopharmaceutical innovations: Do biologics differ from small molecules? (Article 4). Forum Health Econ. Policy13(1), 16014 (2010).
  • Kozlowski S , WoodcockJ, MidthunK, ShermanRB. Developing the nation‘s biosimilars program. N. Engl. J. Med.365(5), 385–388 (2011).
  • Trivigno D , EssmannF, HuberS, RudnerJ. The deubiquitinase USP9x controls Mcl-1 levels in response to ionizing radiation. In: Cell Death in Cancer. De Rode Hoed, Amsterdam, The Netherlands (2012).
  • Naumann I , KapplerR, von Schweinitz D, Debatin KM, Fulda S. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin. Cancer Res.17(10), 3204–3218 (2011).
  • Certo M , Del Gaizo Moore V, Nishino M et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell9(5), 351–365 (2006).
  • Vrielink J , HeinsMS, SetroikromoRet al. Synthetic constrained peptide selectively binds and antagonizes death receptor 5. FEBS J. 277(7), 1653–1665 (2010).
  • Neuzil J , WangXF, DongLF, LowP, RalphSJ. Molecular mechanism of ‘mitocan‘-induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl-2 family proteins. FEBS Lett.580(22), 5125–5129 (2006).
  • Chipuk JE , GreenDR. Dissecting p53-dependent apoptosis. Cell Death Differ.13(6), 994–1002 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.